Back to search results
NCT07381985

Strategy for Management of Patients With Hereditary Cancer Syndromes (HCS) in a Rural Environment

Enrolling by Invitation
NAAges 18+InterventionalHealth services
University of Vermont Medical Center
~200 participants
Updated 2026-02-02 on ClinicalTrials.gov
What's tested:Longitudinal Cancer Genetics Follow-Up Program

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adherence to Cancer Prevention and Surveillance Guidelines
Measured over Baseline, 12 months, and 24 months

Conditions

Hereditary Cancer Syndromes
BRCA1 Hereditary Breast and Ovarian Cancer Syndrome
Lynch Syndrome

Explore related trials

BRCA1/2-Associated Hereditary Breast and Ovarian Cancer SyndromeHereditary Neoplastic SyndromeLynch SyndromeGermline Cancer Risk Gene

NCT07381985

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Vermont Medical Center

    Burlington, Vermontno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients of all genders must be ≥ 18 years of age.
Patients must have a known pathogenic germline variant in a cancer risk gene that was identified by a CLIA-approved lab more than one year ago.
Patients must be able to accurately provide self-report data (i.e., per clinical judgment, cognitive function is intact).
Patients must be able to complete questionnaires in English.
Patients must have the ability to provide informed consent.

What this trial measures

  • Adherence to Cancer Prevention and Surveillance GuidelinesBaseline, 12 months, and 24 months

    Proportion of participants who are adherent to National Comprehensive Cancer Network (NCCN) guideline-recommended cancer risk-reducing strategies-including surveillance imaging, colonoscopy, chemoprevention, and prophylactic surgeries-measured at baseline, 12 months, and 24 months. Adherence will be determined through a gene-specific adherence survey completed during clinic visits and supported by clinical documentation.